DCF Valuation
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) DCF Valuation — Is AMRX overvalued?
The estimated DCF fair value of one Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) share is $11.78. Compared to the current market price of $18.46, the stock is overvalued by 36.2%.
DCF fair value
$11.78
Market price
$18.46
Upside / downside
−36.2%
Prefer the inverse question? See what growth rate the market is pricing into AMRX →
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) DCF valuation FAQ
What is the DCF fair value of Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX)?
The discounted-cash-flow model estimates the intrinsic fair value of one Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) share at $11.78, based on a 10-year projection of its cash flows converging to Damodaran industry averages.
Is Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) overvalued or undervalued?
Against the current market price of $18.46, the DCF fair value of $11.78 implies AMRX is overvalued by 36.2%.
How is the AMRX DCF value calculated?
It is a 10-year discounted-cash-flow estimate built from Amneal Pharmaceuticals, Inc. Class A Common Stock's reported fundamentals, with terminal assumptions anchored to Damodaran NYU industry datasets. The market price refreshes daily; the DCF fair value updates when Amneal Pharmaceuticals, Inc. Class A Common Stock files a new quarterly or annual report.
How this AMRX valuation is built
The model projects ten years of Amneal Pharmaceuticals, Inc. Class A Common Stock's free cash flow to the firm and discounts each year at its own cost of capital. Rather than assuming today's growth and margins persist forever, a moat-scoring step — weighing Amneal Pharmaceuticals, Inc. Class A Common Stock's ROIC-versus-WACC spread, gross-margin trend, and reinvestment efficiency — decides how many years the business holds its edge before its economics mean-revert toward the Damodaran NYU benchmarks for its industry.
WACC is rebuilt each year from an unlevered-then-relevered beta and the company's evolving capital structure; terminal value uses the Gordon growth model with a reinvestment rate tied to the return earned on new capital (goodwill stripped out to reflect operating efficiency). Every assumption — growth, margins, tax, leverage, convergence timing — is editable, and running the full interactive model adds a 10,000-draw Monte Carlo simulation and WACC-versus-terminal-growth sensitivity heatmaps.
The market price refreshes daily; the DCF fair value updates when Amneal Pharmaceuticals, Inc. Class A Common Stock files a new quarterly or annual report. For educational/informational purposes only — not investment advice. Last updated 2026-08-06.